| Atai Life Sciences N.V. (ATAI) | |||
|---|---|---|---|
| 4.43 0.05 (1.14%) | 08-08 16:00 | ||
| Open: | 4.5 | Pre. Close: | 4.38 |
| High: | 4.86 | Low: | 4.3914 |
| Volume: | 1,753,038 | Market Cap: | 712M |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 4.863 - 4.877 | 4.877 - 4.893 |
| Low: | 4.349 - 4.366 | 4.366 - 4.384 |
| Close: | 4.401 - 4.426 | 4.426 - 4.453 |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 5.68  One year: 6.63 |
| Support: | Support1: 4.03 Support2: 3.51 |
| Resistance: | Resistance1: 4.86 Resistance2: 5.68 |
| Pivot: | 4.01 |
| Moving Averages: | MA(5): 4.15 MA(20): 4.05 MA(100): 4.17  MA(250): 8.07 |
| MACD: | MACD(12,26): 0.07 Signal(12,26,9): 0.04 |
| %K %D: | %K(14,3): 71.72 %D(3): 61.24 |
| RSI: | RSI(14): 62.08 |
| 52-Week: | High: 17.9 Low: 2.95 Change(%): -70.0 |
| Average Vol(K): | 3-Month: 824 10-Days: 953 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ATAI ] has closed below upper band by 10.2%. Bollinger Bands are 0.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Stock chart |
|---|
 |
| Stock News |
|---|
|
Fri, 05 Aug 2022 Midday Report: ATAI Life N.V. (ATAI) Shares Up on August 5 - Equities News Thu, 28 Jul 2022 7 Psychedelic Stocks to Watch - WTOP Fri, 22 Jul 2022 New Regulations for Psychedelics? Here's What Investors Need to Know - Nasdaq Mon, 18 Jul 2022 Should You Buy ATAI Life Sciences NV (ATAI) Stock Monday Morning? - InvestorsObserver Thu, 14 Jul 2022 ATAI Life Sciences NV (ATAI) Stock: What Does the Chart Say Thursday? - InvestorsObserver Tue, 12 Jul 2022 Cathie Wood Watch: Ark Buys Big Into Biotech - TheStreet |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | 160.73 |
| % Held by Insiders | 132380000.00 |
| % Held by Institutions | 9.41 |
| Shares Short (K) | 4380 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -158690000.000 |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | -32.00 |
| Return on Assets (ttm) | 13.9 |
| Return on Equity (ttm) | -37.5 |
| Qtrly Rev. Growth | 496000.0 |
| Gross Profit (p.s.) | 0.127 |
| Sales Per Share | 0.127 |
| EBITDA (p.s.) | -0.750 |
| Qtrly Earnings Growth | -1.40 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | -70.71 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | 34.84 |
| Price to Cash Flow | |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 5140000.000 |
